Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
2 hedge funds and large institutions have $367K invested in Oasmia Pharmaceutical AB in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
21% less capital invested
Capital invested by funds: $467K → $367K (-$100K)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.99K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1K |
OASM Hedge Fund Activity: Q3 2016 in Review
2 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q3 2016, worth a combined $367K — down 21% from $467K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of OASM and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $39K sold.
- 2 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q3 2016, down from 4 in Q2 2016.
- Funds reported $367K of Oasmia Pharmaceutical AB stock for Q3 2016, down 21% quarter-over-quarter.
- 0 funds opened new Oasmia Pharmaceutical AB positions in Q3 2016 and 2 closed out, a net change of -2 holders.
- The largest Oasmia Pharmaceutical AB seller in Q3 2016 was Citadel Advisors, an estimated $39K sold.
Based on aggregated 13F filings for Q3 2016.